Rachel N Criner1, Wassim W Labaki2, Elizabeth A Regan3, Jessica M Bon4, Xavier Soler5, Surya P Bhatt6, Susan Murray7, John E Hokanson8, Edwin K Silverman9, James D Crapo3, Jeffrey L Curtis2,10, Fernando J Martinez2, Barry J Make3, MeiLan K Han2, Carlos H Martinez2. 1. Department of Internal Medicine, University of Michigan, Ann Arbor. 2. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor. 3. Division of Pulmonary Medicine, National Jewish Health, Denver, Colorado. 4. Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego. 6. Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama, Birmingham. 7. School of Public Health, University of Michigan, Ann Arbor. 8. School of Public Health, University of Colorado, Aurora. 9. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 10. Veterans' Administration Ann Arbor Healthcare System, Ann Arbor, Michigan.
Abstract
Background: The Global initiative for chronic Obstructive Lung Disease (GOLD) ABCD groupings were recently modified. The GOLD 2011 guidelines defined increased risk as forced expiratory volume in 1 second (FEV1) < 50% predicted or ≥ 2 outpatient or ≥ 1 hospitalized exacerbation in the prior year, whereas the GOLD 2017 guidelines use only exacerbation history. We compared mortality and exacerbation rates in the Genetic Epidemiology of COPD Study cohort (COPDGene®) by 2011 (exacerbation history/FEV1 and dyspnea) versus 2017 (exacerbations and dyspnea) classifications. Methods: Using data from COPDGene®, we tested associations of ABCD groups with all-cause mortality (Cox models, adjusted for age, sex, race and comorbidities) and longitudinal exacerbations (zero-inflated Poisson models). Results: In 4469 individuals (mean age 63.1 years, 44% female), individual distributions in 2011 versus 2017 systems were: A, 32.0% versus 37.0%; B, 17.6% versus 36.3%; C, 9.4% versus 4.4%; D, 41.0% versus 22.3%; (observed agreement 76% [expected 27.8%], Kappa 0.67, p<0.001). Individuals in group D-2011 had 1.1 ± 1.6 exacerbations/year (mean ± standard deviation [SD]) versus 1.4 ± 1.8 for D-2017 (median follow-up 3.7 years). Using group A as reference, for both systems, mortality (median follow-up 6.8 years) was highest in group D (D-2011, [hazard ratio] HR 5.2 [95% confidence interval (CI) 4.2, 6.4]; D-2017, HR 5.5 [4.5, 6.8]), lowest for group C (HR 1.9 [1.4, 2.6] versus HR 1.9 [1.3, 2.8]) and intermediate for group B (HR 2.6 [2.0, 3.4] versus HR 3.4 [2.8, 4.1]). GOLD 2011 had better mortality discrimination (area under the curve [AUC] 0.68) than GOLD 2017 (AUC 0.66, p<0.001 for comparison) but similar exacerbation rate prediction. Conclusions: Relative to the GOLD 2011 consensus statement, discriminate predictive power of the 2017 ABCD classification is similar for exacerbations but lower for survival.
Background: The Global initiative for chronic Obstructive Lung Disease (GOLD) ABCD groupings were recently modified. The GOLD 2011 guidelines defined increased risk as forced expiratory volume in 1 second (FEV1) < 50% predicted or ≥ 2 outpatient or ≥ 1 hospitalized exacerbation in the prior year, whereas the GOLD 2017 guidelines use only exacerbation history. We compared mortality and exacerbation rates in the Genetic Epidemiology of COPD Study cohort (COPDGene®) by 2011 (exacerbation history/FEV1 and dyspnea) versus 2017 (exacerbations and dyspnea) classifications. Methods: Using data from COPDGene®, we tested associations of ABCD groups with all-cause mortality (Cox models, adjusted for age, sex, race and comorbidities) and longitudinal exacerbations (zero-inflated Poisson models). Results: In 4469 individuals (mean age 63.1 years, 44% female), individual distributions in 2011 versus 2017 systems were: A, 32.0% versus 37.0%; B, 17.6% versus 36.3%; C, 9.4% versus 4.4%; D, 41.0% versus 22.3%; (observed agreement 76% [expected 27.8%], Kappa 0.67, p<0.001). Individuals in group D-2011 had 1.1 ± 1.6 exacerbations/year (mean ± standard deviation [SD]) versus 1.4 ± 1.8 for D-2017 (median follow-up 3.7 years). Using group A as reference, for both systems, mortality (median follow-up 6.8 years) was highest in group D (D-2011, [hazard ratio] HR 5.2 [95% confidence interval (CI) 4.2, 6.4]; D-2017, HR 5.5 [4.5, 6.8]), lowest for group C (HR 1.9 [1.4, 2.6] versus HR 1.9 [1.3, 2.8]) and intermediate for group B (HR 2.6 [2.0, 3.4] versus HR 3.4 [2.8, 4.1]). GOLD 2011 had better mortality discrimination (area under the curve [AUC] 0.68) than GOLD 2017 (AUC 0.66, p<0.001 for comparison) but similar exacerbation rate prediction. Conclusions: Relative to the GOLD 2011 consensus statement, discriminate predictive power of the 2017 ABCD classification is similar for exacerbations but lower for survival.
Entities:
Keywords:
Global initiative for chronic Obstructive Lung Dis; chronic obstructive pulmonary disease; copd; exacerbation mortality
Authors: David C LaFon; Surya P Bhatt; Wassim W Labaki; Farbod N Rahaghi; Matthew Moll; Russ P Bowler; Elizabeth A Regan; Barry J Make; James D Crapo; Raul San Jose Estepar; Alejandro A Diaz; Edwin K Silverman; MeiLan K Han; Brian Hobbs; Michael H Cho; George R Washko; Mark T Dransfield; J Michael Wells Journal: Eur Respir J Date: 2020-02-12 Impact factor: 16.671
Authors: Thomas Keller; Laura J Spece; Lucas M Donovan; Edmunds Udris; Scott S Coggeshall; Matthew Griffith; Alexander D Bryant; Richard Casaburi; J Allen Cooper; Gerard J Criner; Philip T Diaz; Anne L Fuhlbrigge; Steven E Gay; Richard E Kanner; Fernando J Martinez; Ralph J Panos; David Shade; Alice Sternberg; Thomas Stibolt; James K Stoller; James Tonascia; Robert Wise; Roger D Yusen; David H Au; Laura C Feemster Journal: Chest Date: 2020-04-09 Impact factor: 9.410
Authors: Hamish McAuley; Kate Hadley; Omer Elneima; Christopher E Brightling; Rachael A Evans; Michael C Steiner; Neil J Greening Journal: ERJ Open Res Date: 2021-01-18
Authors: Elena García Castillo; Tamara Alonso Pérez; Julio Ancochea; Maria Teresa Pastor Sanz; Pere Almagro; Pablo Martínez-Camblor; Marc Miravitlles; Mónica Rodríguez-Carballeira; Annie Navarro; Bernd Lamprecht; Ana S Ramírez-García Luna; Bernhard Kaiser; Inmaculada Alfageme; Ciro Casanova; Cristóbal Esteban; Juan J Soler-Cataluña; Juan P de-Torres; Bartolomé R Celli; Jose M Marín; Gerben Ter Riet; Patricia Sobradillo; Peter Lange; Judith Garcia-Aymerich; Josep M Anto; Alice M Turner; MeiLan K Han; Arnulf Langhammer; Sigrid Anna Aalberg Vikjord; Alice Sternberg; Linda Leivseth; Per Bakke; Ane Johannessen; Toru Oga; Borja G Cosío; Andrés Echazarreta; Nicolás Roche; Pierre-Régis Burgel; Don D Sin; Milo A Puhan; Jose Luis López-Campos; Laura Carrasco; Joan B Soriano Journal: ERJ Open Res Date: 2020-11-02
Authors: Arnulf Langhammer; Ben Michael Brumpton; Laxmi Bhatta; Linda Leivseth; Xiao-Mei Mai; Anne Hildur Henriksen; David Carslake; Yue Chen Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-01-31